Dupixent Comprehensive Forecast on the Accelerating Market Growth for Asthma by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Dupixent providing insights into the drug market landscape and market forecast of Dupixent upto 2034. The report, titled " Dupixent Sales Forecast, and Market Size Analysis - 2034" is now available for review and analysis.

Are you interested in finding out the projected market size of Dupixent in 2034? Dupixent Market Forecast @ https://www.delveinsight.com/sample-request/dupixent-market-size-forecast-and-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Factors Driving Dupixent Growth
1. Market Share Gains and New Patient Starts
• Dupixent continues to achieve strong market share growth across multiple immunology and inflammatory conditions.
• A steady rise in new patient starts is fueling robust prescription demand, particularly in dermatology and respiratory indications.
• Sanofi and Regeneron's expansive commercial strategy, physician engagement programs, and patient support services are further boosting adoption.

2. Expansion Across Key Indications
• Atopic Dermatitis: Dupixent remains the leading therapy for moderate-to-severe atopic dermatitis globally, with significant penetration in both adult and pediatric populations.
• Asthma: Widely prescribed as an add-on therapy for moderate-to-severe asthma, showing strong uptake due to its targeted mechanism of action and proven efficacy in reducing exacerbations.
• Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP): Established as a go-to therapy in this underserved segment, with growing patient volumes.
• Eosinophilic Esophagitis (EoE): Recently approved use is expanding Dupixent's presence in gastroenterology.
• Chronic Spontaneous Urticaria (CSU): Ongoing development in this space positions Dupixent to further strengthen its dermatology portfolio.
• Pipeline developments also point to potential future applications in COPD and other allergic/inflammatory conditions, expanding Dupixent's reach.

For More Information about Dupixent Market Report @ https://www.delveinsight.com/sample-request/dupixent-market-size-forecast-and-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Dupixent Market Report offers projected sales forecasts for Dupixent for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

Dupixent Recent Developments
• In June 2025, Just over three-quarters, 76%, of patients receiving Sanofi and Regeneron's Dupixent (dupilumab) achieved at least a 75% improvement in overall disease severity (EASI-75), the primary endpoint of the DISCOVER Phase IV study.
• In April 2025, the US Food and Drug Administration (FDA) approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.
• In March 2025, Regeneron Pharmaceuticals and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy.

What is Dupixent Prescribed for?
Dupixent (dupilumab) is a prescription biologic medication used to treat several chronic inflammatory diseases driven by type 2 inflammation. It is commonly prescribed for moderate-to-severe atopic dermatitis (eczema) in patients whose symptoms are not adequately controlled with topical therapies. In addition, Dupixent is used as an add-on maintenance treatment for moderate-to-severe asthma, particularly in patients with eosinophilic asthma or those dependent on oral corticosteroids. The drug is also approved for chronic rhinosinusitis with nasal polyps, where it helps reduce inflammation and nasal blockage, and for eosinophilic esophagitis, a condition that causes inflammation in the esophagus and difficulty swallowing. The report extensively covers the details and developments related to Dupixent, capturing important highlights on developmental pipeline, regulatory status and special designations of Dupixent, route of administration, safety and efficacy details.

Dupixent Market Assessment
This report provides a detailed market assessment of Dupixent for Asthma, Atopic dermatitis, Chronic obstructive pulmonary disease, Chronic Urticaria, Eosinophilic Esophagitis, Prurigo Nodularis, Rhinosinusitis, Ulcerative colitis and Aspergillosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2020 to 2034.

Dupixent Clinical Assessment
The report provides the clinical trials information of Dupixent for Asthma, Atopic dermatitis, Chronic obstructive pulmonary disease, Chronic Urticaria, Eosinophilic Esophagitis, Prurigo Nodularis, Rhinosinusitis, Ulcerative colitis and Aspergillosis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

Do you know your drug's competitive positioning against Dupixent? Dupixent Drugs Insights- https://www.delveinsight.com/sample-request/dupixent-market-size-forecast-and-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dupixent Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Dupixent.

Dupixent Market Size in the US
A dedicated section of the report focuses on the expected market size of Dupixent for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Why you should buy Dupixent Market Report
• The report provides future market assessments for Dupixent for Asthma, Atopic dermatitis, Chronic obstructive pulmonary disease, Chronic Urticaria, Eosinophilic Esophagitis, Prurigo Nodularis, Rhinosinusitis, Ulcerative colitis and Aspergillosis in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies.
• Leading Dupixent for Asthma, Atopic dermatitis, Chronic obstructive pulmonary disease, Chronic Urticaria, Eosinophilic Esophagitis, Prurigo Nodularis, Rhinosinusitis, Ulcerative colitis and Aspergillosis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Dupixent
• Discover the competitive landscape of Dupixent through 7MM
• Get a Thorough Analysis of the Dupixent Development pipeline, Safety & Efficacy of the Dupixent, and ROA
• Thorough Dupixent market forecast will help understand how drug is competing with other emerging Dupixent
• Get analysis of the Dupixent clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.